Compare OFIX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | FULC |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 467.8M |
| IPO Year | 1998 | 2019 |
| Metric | OFIX | FULC |
|---|---|---|
| Price | $9.86 | $3.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $17.25 | $16.38 |
| AVG Volume (30 Days) | 402.5K | ★ 3.8M |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $8.85 | $2.83 |
| 52 Week High | $16.99 | $15.74 |
| Indicator | OFIX | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 38.11 |
| Support Level | $8.99 | $2.83 |
| Resistance Level | $9.90 | $4.02 |
| Average True Range (ATR) | 0.45 | 0.22 |
| MACD | 0.12 | 0.14 |
| Stochastic Oscillator | 88.39 | 54.70 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.